



Lialda[®] (mesalamine) – First-time generic

- The [FDA approved](#) Zydus' [AB-rated](#) generic to Shire's [Lialda \(mesalamine\)](#) 1.2 gram delayed-release tablets, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.
- Mesalamine is also available as generic [800 mg delayed-release tablets](#), generic [4 gm/60 mL rectal enema](#), brand 250 mg and 500 mg extended-release capsules ([Pentasa[®]](#)), brand 1,000 mg rectal suppository ([Canasa[®]](#)), brand 400 mg delayed-release tablets ([Delzicol[®]](#)), and brand 0.375 gram extended-release capsules ([Apriso[®]](#)).
- Refer to individual drug labels for specific indications.
- According to Shire's [annual report](#), 2016 worldwide annual sales for Lialda were \$792.1 million.
- Generic Lialda is estimated to launch in the second half of 2017.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.